Largest pharmaceutical companies in the United States by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 44 pharmaceutical companies in the United States ranked by total liabilities, at CHF 115.6B, ahead of Pfizer (CHF 102.3B) and Johnson & Johnson (CHF 99.2B). Figures as of 20 Nov 2026, 03:16 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 44
- First
- AbbVieCHF 115.6B
- Median
- CHF 701.9M
- Combined market value
- CHF 3.15T
- Countries
- 1
Market values as of .
United States▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | CHF 115.6B | CHF 422.4B | CHF 238.96 | 0.86% down | 25% up | ||
| 2 | PfizerPFE · Health Care | CHF 102.3B | CHF 132.3B | CHF 23.21 | 1.85% down | 15% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | CHF 99.2B | CHF 542B | CHF 225.14 | 2.04% down | 34% up | ||
| 4 | Eli LillyLLY · Health Care | CHF 72.4B | CHF 1.01T | CHF 1,138.70 | 2.29% down | 33% up | ||
| 5 | Merck & CoMRK · Health Care | CHF 71B | CHF 275.9B | CHF 111.93 | 3.61% down | 45% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | CHF 60.3B | CHF 100.5B | CHF 49.17 | 2.05% down | 30% up | ||
| 7 | Abbott LaboratoriesABT · Health Care | CHF 28.6B | CHF 151.6B | CHF 87.54 | 0.58% down | 16% down | ||
| 8 | ViatrisVTRS · Health Care | CHF 18.9B | CHF 19.2B | CHF 16.75 | 1.97% down | 99% up | ||
| 9 | ZoetisZTS · Health Care | CHF 10.2B | CHF 27.7B | CHF 68.09 | 5.59% down | 26% down | ||
| 10 | Royalty PharmaRPRX · Health Care | CHF 8.3B | CHF 32.8B | CHF 57.07 | 1.38% down | 79% up | ||
| 11 | Regeneron PharmaceuticalsREGN · Health Care | CHF 7.8B | CHF 80.5B | CHF 778.17 | 2.35% down | 28% up | ||
| 12 | Vertex PharmaceuticalsVRTX · Health Care | CHF 5.9B | CHF 111.3B | CHF 438.80 | 2.94% down | 27% up | ||
| 13 | Elanco Animal HealthELAN · Health Care | CHF 5.7B | CHF 11.1B | CHF 22.16 | 1.54% down | 26% up | ||
| 14 | Alnylam PharmaceuticalsALNY · Health Care | CHF 3.5B | CHF 16.7B | CHF 124.58 | 1.06% down | 66% down | ||
| 15 | Amneal PharmaceuticalsAMRX · Health Care | CHF 3.1B | CHF 6.3B | CHF 18.03 | 2.24% down | 90% up | ||
| 16 | PTC TherapeuticsPTCT · Health Care | CHF 2.6B | CHF 4.1B | CHF 49.16 | 3.16% down | 21% down | ||
| 17 | Ionis PharmaceuticalsIONS · Health Care | CHF 2.6B | CHF 3.8B | CHF 22.94 | 0.62% down | 63% down | ||
| 18 | BridgeBio PharmaBBIO · Health Care | CHF 2.5B | CHF 12.8B | CHF 65.89 | 0.22% up | 21% up | ||
| 19 | CytokineticsCYTK · Health Care | CHF 1.8B | CHF 6B | CHF 43.37 | 0.27% up | 19% down | ||
| 20 | InsmedINSM · Health Care | CHF 1.3B | CHF 26.7B | CHF 121.75 | 20.58% up | 40% down | ||
| 21 | BioMarin PharmaceuticalBMRN · Health Care | CHF 1.3B | CHF 10B | CHF 51.76 | 0.02% down | 17% up | ||
| 22 | Arrowhead PharmaceuticalsARWR · Health Care | CHF 743.2M | CHF 5.2B | CHF 36.79 | 1.25% up | 13% up | ||
| 23 | United TherapeuticsUTHR · Health Care | CHF 660.6M | CHF 20.1B | CHF 471.20 | 3.16% down | 22% up | ||
| 24 | Legend BiotechLEGN · Health Care | CHF 616.6M | CHF 2.6B | CHF 13.57 | 0.92% down | 41% down | ||
| 25 | Madrigal PharmaceuticalsMDGL · Health Care | CHF 553.6M | CHF 7.8B | CHF 334.36 | 0.34% down | 27% down | ||
| 26 | Axsome TherapeuticsAXSM · Health Care | CHF 506.9M | CHF 6B | CHF 114.35 | 1.25% up | 6% down | ||
| 27 | Ligand PharmaceuticalsLGND · Health Care | CHF 458M | CHF 4.8B | CHF 241.83 | 3.94% down | 50% up | ||
| 28 | Mirum PharmaceuticalsMIRM · Health Care | CHF 445.1M | CHF 5.3B | CHF 80.49 | 3.27% up | 34% up | ||
| 29 | Travere TherapeuticsTVTX · Health Care | CHF 413.3M | CHF 3.9B | CHF 40.71 | 3.86% down | 45% up | ||
| 30 | TG TherapeuticsTGTX · Health Care | CHF 350M | CHF 8.3B | CHF 54.68 | 1.88% down | 117% up | ||
| 31 | Cogent BiosciencesCOGT · Health Care | CHF 253.9M | CHF 4.1B | CHF 23.38 | 0.25% down | 20% down | ||
| 32 | Rhythm PharmaceuticalsRYTM · Health Care | CHF 177.1M | CHF 6.8B | CHF 98.44 | 1.88% down | 18% up | ||
| 33 | Corcept TherapeuticsCORT · Health Care | CHF 159.2M | CHF 6B | CHF 54.76 | 4.15% down | 10% down | ||
| 34 | Definium TherapeuticsDFTX · Health Care | CHF 90.8M | CHF 3.4B | CHF 24.85 | 1.24% up | 168% up | ||
| 35 | Summit TherapeuticsSMMT · Health Care | CHF 77.8M | CHF 7.1B | CHF 8.91 | 0.67% up | 36% down | ||
| 36 | ErascaERAS · Health Care | CHF 59.8M | CHF 4.2B | CHF 11.98 | 3.34% up | 395% up | ||
| 37 | Spyre TherapeuticsSYRE · Health Care | CHF 52.7M | CHF 7.8B | CHF 82.28 | 3.77% down | 332% up | ||
| 38 | Praxis Precision MedicinesPRAX · Health Care | CHF 50.4M | CHF 7.3B | CHF 262.02 | 1.87% up | 86% up | ||
| 39 | Protagonist TherapeuticsPTGX · Health Care | CHF 45.1M | CHF 6.8B | CHF 104.52 | 2.47% down | 51% up | ||
| 40 | Dianthus TherapeuticsDNTH · Health Care | CHF 31.6M | CHF 4B | CHF 71.49 | 1.01% up | 108% up | ||
| 41 | Edgewise TherapeuticsEWTX · Health Care | CHF 25.6M | CHF 3.8B | CHF 34.70 | 0.48% down | 86% up | ||
| 42 | Oruka TherapeuticsORKA · Health Care | CHF 14.1M | CHF 5.6B | CHF 82.23 | 1.91% up | 255% up | ||
| 43 | Belite BioBLTE · Health Care | CHF 8.5M | CHF 5.2B | CHF 127.28 | 3.33% down | 43% up | ||
| 44 | VeradermicsMANE · Health Care | CHF 7.7M | CHF 4.4B | CHF 104.83 | 0.38% down | 231% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 0.8428 CHF).
Questions and answers
Which pharmaceutical companies in the United States rank first by total liabilities?
AbbVie (CHF 115.6B), Pfizer (CHF 102.3B) and Johnson & Johnson (CHF 99.2B) are the top three of the 44 pharmaceutical companies in the United States ranked by total liabilities as of 20 Nov 2026, 03:16 UTC.
How many pharmaceutical companies in the United States are in this ranking?
44 are ranked by total liabilities.
What are these pharmaceutical companies in the United States worth together?
The 44 pharmaceutical companies in the United States ranked by total liabilities have a combined market value of CHF 3.15T as of 20 Nov 2026, 03:16 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceutical companies in the United States by total liabilities”, data as of 20 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?country=united-states&by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.